Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
// Zhi-Jie Hou 1,* , Xi Luo 1,* , Wei Zhang 1,* , Fei Peng 1 , Bai Cui 1 , Si-Jin Wu 2 , Fei-Meng Zheng 1 , Jie Xu 1 , Ling-Zhi Xu 1 , Zi-Jie Long 3 , Xue-Ting Wang 1 , Guo-Hui Li 4 , Xian-Yao Wan 5 , Yong-Liang Yang 2 and Quentin Liu 1 1 Institute of Cancer Stem Cell, Dalian Medical University, Dalian, China, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China 2 Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, China 3 Department of Hematology, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou, China 4 Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, The Chinese Academy of Sciences, Dalian, China 5 Department of Critical Care Medicine, the First Affiliated Hospital, Dalian Medical University, Dalian, China * These authors contributed equally to this work Correspondence to: Quentin Liu, email: // Yong-liang Yang, email: // Xian-Yao Wan, email: // Keywords : flubendazole, breast cancer, cancer stem-like cell, cell cycle, tubulin Received : August 23, 2014 Accepted : January 05, 2015 Published : January 21, 2015 Abstract Cancer stem-like cell (CS-like cell) is considered to be responsible for recurrence and drug resistance events in breast cancer, which makes it a potential target for novel cancer therapeutic strategy. The FDA approved flubendazole, has been widely used in the treatment of intestinal parasites. Here, we demonstrated a novel effect of flubendazole on breast CS-like cells. Flubendazole inhibited breast cancer cells proliferation in dose- and time-dependent manner and delayed tumor growth in xenograft models by intraperitoneal injection. Importantly, flubendazole reduced CD44 high /CD24 low subpopulation and suppressed the formation of mammosphere and the expression of self-renewal related genes including c-myc , oct4 , sox2, nanog and cyclinD1 . Moreover, we found that flubendazole induced cell differentiation and inhibited cell migration. Consistently, flubendazole reduced mesenchymal markers (β-catenin, N-cadherin and Vimentin) expression and induced epithelial and differentiation marker (Keratin 18) expression in breast cancer cells. Mechanism study revealed that flubendazole arrested cell cycle at G2/M phase and induced monopolar spindle formation through inhibiting tubulin polymerization. Furthermore, flubendazole enhanced cytotoxic activity of conventional therapeutic drugs fluorouracil and doxorubicin against breast cancer cells. In conclusion, our findings uncovered a remarkable effect of flubendazole on suppressing breast CS-like cells, indicating a novel utilization of flubendazole in breast cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 2×
“Recent studies report that the first-line drugs for treating other disease might be repurposed for targeting CS-like cells in breast cancer [32-35].”
BackgroundJiralerspong, S., Palla, S. L., Giordano, S. H., Meric-Bernstam, F., Liedtke, C., Barnett, C. M., Hsu, L., Hung, M.-C., Hortobagyi, G. N., & Gonzalez-Angulo, A. M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.19.6410 · Cited by 880 · cited 2×
“Recent studies report that the first-line drugs for treating other disease might be repurposed for targeting CS-like cells in breast cancer [32-35].”
BackgroundLacey, E. (1988) · International Journal for Parasitology · doi:10.1016/0020-7519(88)90175-0 · Cited by 560 · cited 1×
“It disrupts tubulin polymerization by showing preference for binding to nematode tubulin rather than the tubulin in host [26, 27].”
BackgroundHirsch, H. A., Iliopoulos, D., & Struhl, K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1221055110 · Cited by 440 · cited 2×
“Metformin suppressed tumor growth in xenografts by preferentially inhibiting nuclear translocation of NFκB and phosphorylation of STAT3 in cancer stem cells [34].”
BackgroundZhang, X.-Y., Varthi, M., Sykes, S. M., Phillips, C., Warzecha, C., Zhu, W., Wyce, A., Thorne, A. W., Berger, S. L., & McMahon, S. B. (2008) · Molecular Cell · doi:10.1016/j.molcel.2007.12.015 · Cited by 427 · cited 2×
“For instance, depletion of the CS-like cell marker USP22 arrests cell cycle at G1 phase in lung cancer cells [16].”
BackgroundAntiprotozoal activities of benzimidazoles and correlations with beta-tubulin sequence
Katiyar, S. K., Gordon, V. R., McLaughlin, G. L., & Edlind, T. D. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.9.2086 · Cited by 217
Cited by
Cancer stem cell (CSC) resistance drivers
Najafi, M., Mortezaee, K., & Majidpoor, J. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116781 · Cited by 466
The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Chen, J.-F., Luo, X., Xiang, L.-S., Li, H.-T., Zha, L., Li, N., He, J.-M., Xie, G.-F., Xie, X., & Liang, H.-J. (2106) · Oncotarget · doi:10.18632/oncotarget.9236 · Cited by 74
Self-citationNath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Metadata
- Authors
- Hou, Z.-J., Luo, X., Zhang, W., Peng, F., Cui, B., Wu, S.-J., Zheng, F.-M., Xu, J., Xu, L.-Z., Long, Z.-J., Wang, X.-T., Li, G.-H., Wan, X.-Y., Yang, Y.-L., & Liu, Q.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-01-21
- Volume
- 6
- Issue
- 8
- Pages
- 6326-6340
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1654551777
- Cited by
- 88
- References
- 6
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.